Global U.S Bacterial Conjunctivitis Drugs Market - Size, Share, Analysis, Trends to 2024
- Submitted by: justinbarnes123
- Views: 79
- Category: Other
- Date Submitted: 02/01/2016 11:11 PM
- Pages: 14
- Report this Essay
Global U.s Bacterial Conjunctivitis Drugs Market - Future market
size in the U.S. is expected to grow (2024)
Persistence Market Research
Global U.s Bacterial Conjunctivitis Drugs
Market is expected to progress a market
worth of USD 439.8 million in 2024 Persistence Market Research
Persistence Market Research
1
Global U.s Bacterial Conjunctivitis Drugs Market - Future market
size in the U.S. is expected to grow (2024)
Persistence Market Research Released New Market Report “The U.S Market Study on
Bacterial Conjunctivitis Drugs -
fluoroquinolones to be the Largest Segment by
2024” the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million
in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR
of2.7%from 2012 to 2018 and (-3.73%) from 2018 to 2024.
Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the
outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into
three major categories: infective (viral and bacterial), allergic, and irritant (chemical).
Bacterial conjunctivitis is one of the most commonly observed eye problems across all age
groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata,
Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As
reported by Healio (specialty medical news and journal publisher), approximately 5 million
acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence
of bacterial conjunctivitis in the country demands effective medications, thereby driving the
growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the
increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in
the U.S. is likely to witness negative growth due to the patent expirations of major
blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few...
size in the U.S. is expected to grow (2024)
Persistence Market Research
Global U.s Bacterial Conjunctivitis Drugs
Market is expected to progress a market
worth of USD 439.8 million in 2024 Persistence Market Research
Persistence Market Research
1
Global U.s Bacterial Conjunctivitis Drugs Market - Future market
size in the U.S. is expected to grow (2024)
Persistence Market Research Released New Market Report “The U.S Market Study on
Bacterial Conjunctivitis Drugs -
fluoroquinolones to be the Largest Segment by
2024” the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million
in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR
of2.7%from 2012 to 2018 and (-3.73%) from 2018 to 2024.
Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the
outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into
three major categories: infective (viral and bacterial), allergic, and irritant (chemical).
Bacterial conjunctivitis is one of the most commonly observed eye problems across all age
groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata,
Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As
reported by Healio (specialty medical news and journal publisher), approximately 5 million
acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence
of bacterial conjunctivitis in the country demands effective medications, thereby driving the
growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the
increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in
the U.S. is likely to witness negative growth due to the patent expirations of major
blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few...